Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | VDR | P11473 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5776100 | 0.91 | SIRT2 (0.45) | SIRT2SIRT1RPS6KB1NR1H4L3MBTL1 | |
| SCHEMBL4125821 | 0.90 | L3MBTL1 (0.49) | NR1H4L3MBTL1VDR | |
| SCHEMBL4140386 | 0.89 | SIRT2 (0.42) | SIRT2SIRT1RPS6KB1NR1H4L3MBTL1 | |
| SCHEMBL4137916 | 0.85 | MAPT (0.46) | SIRT2SIRT1RPS6KB1NR1H4L3MBTL1 | |
| SCHEMBL4123368 | 0.84 | L3MBTL1 (0.51) | SIRT2SIRT1RPS6KB1L3MBTL1PTGER4 | |
| SCHEMBL4125616 | 0.83 | BMPR2 (0.44) | SIRT2SIRT1RPS6KB1L3MBTL1TP53 | |
| SCHEMBL4518317 | 0.82 | RPS6KB1 (0.42) | SIRT2SIRT1RPS6KB1NR1H4L3MBTL1 | |
| SCHEMBL4140385 | 0.82 | RPS6KB1 (0.40) | SIRT2SIRT1RPS6KB1L3MBTL1SIRT3 | |
| SCHEMBL4124971 | 0.81 | L3MBTL1 (0.48) | SIRT2SIRT1RPS6KB1L3MBTL1PTGER4 | |
| SCHEMBL4122876 | 0.81 | L3MBTL1 (0.52) | NR1H4L3MBTL1VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511145-B2 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2009-03-26 | — | — | US | disclosed |
| EP-1651631-A1 | BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE | GENELABS TECHNOLOGIES, INC. (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2005012288-A1 | BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE | GENELABS TECHNOLOGIES, INC (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | HAVCR2, MAVS, ZC3HAV1 | SIRT2 1825/4885SIRT1 2539/4885RPS6KB1 3007/4885 |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | HAVCR2, MAVS, ZC3HAV1 | SIRT2 1825/4885SIRT1 2539/4885RPS6KB1 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.